Fierce Pharma

JUNE 1, 2024

After Enhertu pioneered the HER2-low category in breast cancer treatment, AstraZeneca and Daiichi Sankyo are now hopeful that the antibody-drug conjugate can reach tumors with an even lower express | After Enhertu pioneered the HER2-low category in breast cancer treatment, AstraZeneca and Daiichi Sankyo are now hopeful that the antibody-drug conjugate can reach tumors with an even lower expression of the protein biomarker.

297

297

PharmaTech

JUNE 1, 2024

CGT Catapult will implement Cellular Origins' robotic platform in its Stevenage, UK, site to establish automated CGT manufacturing.

Manufacturing 52

Manufacturing 52

Fierce Pharma

JUNE 1, 2024

Almost 10 years ago, Merck ushered superstar cancer drug Keytruda across the FDA finish line for the first time, starting down a path that would ultimately yield dozens of additional approvals | The Inflation Reduction Act's price negotiation measures stand to cut down drug candidates before they can "grow roots" later in development, Eli Lilly CEO David Ricks said during a panel discussion.

FDA 256

FDA 256

Pharmacy Times

JUNE 1, 2024

This is the largest dataset of pregnancy outcomes for an anti-CD20 therapy in MS, enabling a more comprehensive understanding of ocrelizumab’s safety.

Safety 50

Safety 50

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

JUNE 1, 2024

Armed with two positive phase 3 trial readouts and the hope that at least one will show a significant patient survival benefit, GSK thinks it has the data to convince doctors and the FDA that the o | Armed with two positive phase 3 trial readouts and the hope that at least one will show a significant patient survival benefit, GSK thinks it has the data to convince doctors and the FDA that its once-failed antibody-drug conjugate Blenrep can work in multiple myeloma.

Doctors 213

Doctors FDA Patients 213

Pharmacy Times

JUNE 1, 2024

The addition of ribociclib (Kisqali; Novartis) to endocrine therapy demonstrated a 28% risk reduction in invasive disease-free survival.

46

46